Which countries run stem-cell trials for Scleroderma (Systemic Sclerosis)?

Country distribution

A study with sites in several countries is counted once per country, taken from the location block of each registry record.

What the map means for Scleroderma (Systemic Sclerosis)

Work concentrates in accredited transplant centres with pulmonary and cardiac assessment on site. This is not an intervention that can responsibly be delivered as a travel package.

Where recruitment is actually open

What travelling for a trial actually involves

Cross-border participation fails on logistics more often than on eligibility: follow-up schedules, local insurance, visa duration and who pays for complications. A site that cannot answer those in writing is not going to enrol you.

Multi-country studies, named

Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.

• NCT05016804 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis (Antigua and Barbuda, Argentina)
• NCT04464434 — Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (Italy, Netherlands, United Kingdom)

Why trial geography is not a shortlist

The map is drawn by policy and money. Permissive or well-defined regulatory pathways attract registrations and large research budgets attract more still. None of that transfers to the private clinic advertising in the same city, which may operate under no comparable supervision.

Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.

When these studies started

Registrations by start year since 2020: 2020 (2), 2021 (2), 2022 (4), 2023 (1), 2024 (2), 2025 (3), 2026 (4). Activity for this condition spans 1999 to 2026, which shows whether interest is growing, flat or past its peak.

Frequently asked

Which countries run stem-cell trials for Scleroderma (Systemic Sclerosis)?

Sites are registered in 16 countries; the largest is United States (~49% of country mentions, 2026-08-29).

Does a country with many trials mean better treatment there?

No. Registration volume reflects the research and regulatory environment, not the quality of care a private clinic there will provide.

Are trial sites and commercial clinics the same thing?

Mostly no. Some clinics imply an association with local research institutions; the registry record names the actual sponsor and site, which settles it.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.